Frits M E Franssen1, Joan B Soriano2, Nicolas Roche3, Paul H Bloomfield4, Guy Brusselle5, Leonardo M Fabbri6, Francisco García-Rio7, Mark T Kearney8, Namhee Kwon4, Bo Lundbäck9, Klaus F Rabe10, Alice Raillard11, Hana Muellerova4, John R Cockcroft12. 1. 1 Department of Research and Education, CIRO+, Horn, the Netherlands. 2. 2 Instituto de Investigación Hospital Universitario de la Princesa, Universidad Autónoma de Madrid, Madrid, Spain. 3. 3 Service de Pneumologie, Hôpital Cochin, AP-HP and Université Paris Descartes (EA2511), Sorbonne Paris Cité, Paris, France. 4. 4 Respiratory Franchise Medical, GSK, Uxbridge, United Kingdom. 5. 5 Department of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium. 6. 6 Section of Metabolic Medicine, Department of Medicine, NOCSAE Hospital, AUSMO, Baggiovara, University of Modena and Reggio Emilia, Modena, Italy. 7. 7 Servicio de Neumología, Hospital Universitario La Paz, Universidad Autónoma de Madrid, IdiPAZ, Madrid, Spain. 8. 8 Leeds Multidisciplinary Cardiovascular Research Centre, University of Leeds, Leeds, United Kingdom. 9. 9 Institute of Medicine/Krefting Research Centre, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. 10. 10 LungenClinic Grosshansdorf, Airway Research Centre North, German Centre for Lung Research, Grosshansdorf and Christian-Albrechts University, Kiel, Germany. 11. 11 Direction Médicale de l'Excellence Opérationnelle, GSK, Marly-Le-Roi, France; and. 12. 12 Wales Heart Research Institute, Cardiff University, Cardiff, United Kingdom.
Abstract
RATIONALE: The aim of the ALICE (Airflow Limitation in Cardiac Diseases in Europe) study was to investigate the prevalence of airflow limitation in patients with ischemic heart disease and the effects on quality of life, healthcare use, and future health risk. OBJECTIVES: To examine prebronchodilator and post-bronchodilator spirometry in outpatients aged greater than or equal to 40 years with clinically documented ischemic heart disease who were current or former smokers. METHODS: This multicenter, cross-sectional study was conducted in 15 cardiovascular outpatient clinics in nine European countries. Airflow limitation was defined as post-bronchodilator FEV1/FVC less than 0.70. MEASUREMENTS AND MAIN RESULTS: Among the 3,103 patients with ischemic heart disease who were recruited, lung function was defined for 2,730 patients. Airflow limitation was observed in 30.5% of patients with ischemic heart disease: 11.3% had mild airflow limitation, 15.8% moderate airflow limitation, 3.3% severe airflow limitation, and 0.1% very severe airflow limitation. Most patients with airflow limitation (70.6%) had no previous spirometry testing or diagnosed pulmonary disease. Airflow limitation was associated with greater respiratory symptomatology, impaired health status, and more frequent emergency room visits (P < 0.05). CONCLUSIONS: Airflow limitation compatible with chronic obstructive pulmonary disease affects almost one-third of patients with ischemic heart disease. Although airflow limitation is associated with additional morbidity and societal burden, it is largely undiagnosed and untreated. Clinical trial registered with www.clinicaltrials.gov (NCT 01485159).
RATIONALE: The aim of the ALICE (Airflow Limitation in Cardiac Diseases in Europe) study was to investigate the prevalence of airflow limitation in patients with ischemic heart disease and the effects on quality of life, healthcare use, and future health risk. OBJECTIVES: To examine prebronchodilator and post-bronchodilator spirometry in outpatients aged greater than or equal to 40 years with clinically documented ischemic heart disease who were current or former smokers. METHODS: This multicenter, cross-sectional study was conducted in 15 cardiovascular outpatient clinics in nine European countries. Airflow limitation was defined as post-bronchodilator FEV1/FVC less than 0.70. MEASUREMENTS AND MAIN RESULTS: Among the 3,103 patients with ischemic heart disease who were recruited, lung function was defined for 2,730 patients. Airflow limitation was observed in 30.5% of patients with ischemic heart disease: 11.3% had mild airflow limitation, 15.8% moderate airflow limitation, 3.3% severe airflow limitation, and 0.1% very severe airflow limitation. Most patients with airflow limitation (70.6%) had no previous spirometry testing or diagnosed pulmonary disease. Airflow limitation was associated with greater respiratory symptomatology, impaired health status, and more frequent emergency room visits (P < 0.05). CONCLUSIONS: Airflow limitation compatible with chronic obstructive pulmonary disease affects almost one-third of patients with ischemic heart disease. Although airflow limitation is associated with additional morbidity and societal burden, it is largely undiagnosed and untreated. Clinical trial registered with www.clinicaltrials.gov (NCT 01485159).
Authors: Komal Malik; Susana Diaz-Coto; Maria de la Asunción Villaverde; Pablo Martinez-Camblor; Annie Navarro-Rolon; Francisco Pujalte; Alejandro De la Sierra; Pere Almagro Journal: Int J Chron Obstruct Pulmon Dis Date: 2022-10-14
Authors: Claudia Llontop; Cristina Garcia-Quero; Almudena Castro; Regina Dalmau; Raquel Casitas; Raúl Galera; Alberto Iglesias; Elisabet Martinez-Ceron; Joan B Soriano; Francisco García-Río Journal: PLoS One Date: 2017-08-28 Impact factor: 3.240
Authors: Ulf Nilsson; Nicholas L Mills; David A McAllister; Helena Backman; Caroline Stridsman; Linnea Hedman; Eva Rönmark; Takeshi Fujisawa; Anders Blomberg; Anne Lindberg Journal: Respir Res Date: 2020-06-26